X4 Pharmaceuticals Inc (NASDAQ:XFOR)
| 2.22 Delayed Data As of 3:59pm ET |  +0.19 / +9.36%Today’s Change | 0.65 Today|||52-Week Range 2.41 | +123.56% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Biotechnology | MARKET CAP $249.3M |
Company Description
X4 Pharmaceuticals, Inc. operates as a biotechnology company, which engages in developing human antibodies for treating infectious diseases. The company focuses on restoring healthy immune system function by developing novel therapeutics for the treatment of rare diseases. Its products in pipeline include X4P-001, X4P-002, and X4P-003. The company was founded by Henri A. Termeer, Keith T. Flaherty, Renato T. Skerlj, Richard Peters and Paula Ragan in 2010 and is headquartered in Boston, MA.
Contact Information
X4 Pharmaceuticals, Inc. 61 North Beacon Street Boston Massachusetts 02134 |
Employees
Shareholders
| Other institutional | 22.51% |
| Mutual fund holders | 10.23% |
| Individual stakeholders | 1.20% |
Top Executives
| Paula S. Ragan | President, Chief Executive Officer & Director |
| Mary DiBiase | Chief Operating Officer |
| Adam S. Mostafa | Chief Financial Officer, Secretary & Treasurer |
| Murray Willis Stewart | Director & Chief Medical Officer |
| Art Taveras | Chief Scientific Officer |
